Harbor Advisors LLC Purchases New Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Harbor Advisors LLC purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,500 shares of the medical equipment provider’s stock, valued at approximately $224,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after acquiring an additional 32,551 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Lantheus during the third quarter valued at approximately $25,955,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock valued at $1,041,000 after acquiring an additional 3,772 shares in the last quarter. Empirical Asset Management LLC bought a new stake in shares of Lantheus during the fourth quarter valued at approximately $323,000. Finally, Focus Financial Network Inc. bought a new stake in shares of Lantheus during the fourth quarter valued at approximately $292,000. Institutional investors own 99.06% of the company’s stock.

Insider Activity

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 64,109 shares of company stock valued at $6,110,806 in the last 90 days. Company insiders own 1.50% of the company’s stock.

Lantheus Price Performance

Shares of LNTH stock opened at $97.71 on Friday. Lantheus Holdings, Inc. has a 1 year low of $57.92 and a 1 year high of $126.89. The firm has a fifty day moving average price of $92.67 and a 200-day moving average price of $96.58. The company has a market cap of $6.69 billion, a price-to-earnings ratio of 16.26 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on LNTH shares. JMP Securities reissued a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial lifted their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. Finally, B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and a consensus price target of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.